Table 5.
Type of insulin | Indicators | Public hospital | Primary care institution | Private retailer | Overall | p value* | |
---|---|---|---|---|---|---|---|
Prandial insulin | Human short-acting | MPR | 1.41 ± 0.12 | 1.37 ± 0.13 | 1.52 ± 0.13 | 1.44 ± 0.13† | 0.173 |
Affordability | 4.35 ± 0.37 | 4.24 ± 0.41 | 4.68 ± 0.40 | 4.45 ± 0.40† | |||
Analogs rapid-acting | MPR | 1.69 ± 0.14 | 1.67 ± 0.13 | 1.76 ± 0.32 | 1.70 ± 0.19 | 0.957 | |
Affordability | 6.29 ± 0.53 | 6.19 ± 0.50 | 6.53 ± 1.20 | 6.33 ± 0.69 | |||
Basal insulin | Human intermediate-acting | MPR | 1.49 ± 0.11 | Not Available | 1.57 ± 0.24 | 1.55 ± 0.21† | 0.636 |
Affordability | 4.61 ± 0.35 | Not Available | 4.84 ± 0.75 | 4.77 ± 0.43† | |||
Analogs long-acting | MPR | 2.59 ± 0.33 | 2.23 ± 0.24 | 2.53 ± 0.27 | 2.53 ± 0.32 | 0.155 | |
Affordability | 16.11 ± 1.89 | 14.16 ± 1.53 | 15.72 ± 1.61 | 15.8 ± 01.84 | |||
Pre-mixed insulin | Human | MPR | 1.49 ± 0.40 | 1.28 ± 0.20 | 1.36 ± 0.29 | 1.43 ± 0.36† | 0.018 |
Affordability | 4.61 ± 1.23 | 3.95 ± 0.61 | 4.19 ± 0.90 | 4.43 ± 1.11† | |||
analogs | MPR | 1.59 ± 0.20 | 1.59 ± 0.23 | 1.68 ± 0.21 | 1.62 ± 0..21 | 0.401 | |
Affordability | 5.92 ± 0.75 | 5.91 ± 0.87 | 6.26 ± 0.79 | 6.02 ± 0.76 |
*t tests or ANOVA for data with normal distribution; Kruskal Wallis tests or Mann-Whitney U tests for data with non-normal distribution
† p < 0.001 compared with analogs products